LMNA变异位置与心肌病临床结局的关联
这项多中心回顾性队列研究纳入718例携带可能致病/致病性LMNA变异且无既往恶性室性心律失常的患者,中位随访4.2年。截短变异较错义变异与恶性室性心律失常风险更高相关(HR 1.72),而影响尾部结构域及外显子7-12的错义变异与心律失常风险降低相关。
要点
- 截短LMNA变异患者恶性室性心律失常风险较错义变异高(HR 1.72)。
- 截短变异的位置不影响心律失常或心衰结局。
- 尾部结构域或外显子7-12的错义变异恶性室性心律失常风险更低。
核心结论
- 截短LMNA变异与更差的心律失常结局相关,且独立于变异位置。
- 影响尾部结构域及外显子7-12的错义变异与更好的心律失常和心衰结局相关。
研究设计与样本
- 多中心、回顾性、观察性队列研究,使用国际注册研究(2013年1月起)及三级心肌病中心数据(2000年1月至2017年6月)。
- 纳入718例携带可能致病/致病性LMNA变异且无既往恶性室性心律失常的患者。
主要发现
- 中位随访4.2年期间,223例发生主要结局恶性室性心律失常,109例发生次要结局晚期心衰。
- 截短变异按LMNA基因位置或转录本位置分层,主要和次要结局均无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prior studies have suggested that patients with nonmissense (ie, truncating) variants causing LMNA cardiomyopathy have worse arrhythmic outcomes compared to those with missense variants. However, the effect of the spatial distribution of missense and truncating variants on clinical outcomes remains poorly understood. OBJECTIVE: To determine the association of the spatial distribution of missense and truncating LMNA variants with cardiac outcomes. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, retrospective, observational cohort study used data from an international registry (from January 2013 on) and data derived from tertiary cardiomyopathy centers (January 2000 and June 2017). Patients with likely pathogenic/pathogenic LMNA variants and no prior malignant ventricular arrhythmia (VA) were eligible for inclusion. Data analysis was completed from March 2022 to March 2025. MAIN OUTCOMES AND MEASURES: The primary outcome of time to VA was defined as sudden cardiac death, appropriate implantable cardioverter-defibrillator therapy, or other manifestations of hemodynamically unstable VA. The secondary composite outcome of advanced heart failure was defined as nonsudden cardiac death, implantation of a left ventricular assist device, or cardiac transplant. Outcomes were stratified by type of variant (missense or truncating), affected transcript position (head, rod, or tail), and location on the LMNA gene. RESULTS: A total of 718 patients were included, among whom mean (SD) age was 41.1 (14.3) years, 381 patients (53.1%) were female, and mean (SD) baseline left ventricular ejection fraction was 55.8% (13.3%). Over a median follow-up of 4.2 years, 223 patients experienced the primary outcome of malignant VA and 109 experienced the secondary outcome of advanced heart failure. Patients with truncating variants had a higher risk of VA (hazard ratio [HR], 1.72; 95% CI, 1.19-2.48; P = .004) but no difference in advanced heart failure (HR, 0.94; 95% CI, 0.64-1.40; P = .77) compared with patients with missense variants. There were no significant differences in the primary and secondary outcomes when stratifying truncating variants by location on the LMNA gene or transcript position. In contrast, on multivariable analysis, missense variants affecting the tail domain of LMNA (HR, 0.35; 95% CI, 0.16-0.78; P = .02) and located in exons 7 through 12 (HR, 0.39; 95% CI, 0.17-0.89; P = .035) were associated with a significantly lower risk of the primary outcome of malignant VA. CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, truncating LMNA variants were associated with worse arrhythmic outcomes independent of variant position, whereas missense variants affecting the tail domain and located in exons 7 through 12 had better arrhythmic and heart failure outcomes. Understanding the mechanisms underlying these differences may have future therapeutic implications.
引用
- Bhaskaran A, Ben Yaou R, Helms AS, et al. Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy. JAMA Cardiol. 2025. PMID: 40601341. doi:10.1001/jamacardio.2025.2069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。